S

Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581

Watchlist Manager
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Watchlist
Price: 10.64 CNY -1.39% Market Closed
Market Cap: 7B CNY
Have any thoughts about
Shandong Sinobioway Biomedicine Co Ltd?
Write Note

Shandong Sinobioway Biomedicine Co Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shandong Sinobioway Biomedicine Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Free Cash Flow
-ÂĄ4.9m
CAGR 3-Years
56%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Fufeng Group Ltd
HKEX:546
Free Cash Flow
ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
31%
CAGR 10-Years
N/A
G
GHW International
HKEX:9933
Free Cash Flow
-ÂĄ19.8m
CAGR 3-Years
55%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
Free Cash Flow
-ÂĄ3.4B
CAGR 3-Years
N/A
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Zhejiang XinAn Chemical Industrial Group Co Ltd
SSE:600596
Free Cash Flow
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-5%
A
Anhui Jinhe Industrial Co Ltd
SZSE:002597
Free Cash Flow
-ÂĄ575.8m
CAGR 3-Years
-148%
CAGR 5-Years
N/A
CAGR 10-Years
-40%
No Stocks Found

Shandong Sinobioway Biomedicine Co Ltd
Glance View

Market Cap
7B CNY
Industry
Chemicals

In the bustling world of biotechnology, Shandong Sinobioway Biomedicine Co Ltd stands as a dynamic player, deeply embedded in the heart of China's burgeoning pharmaceutical and biotech sector. Founded with a vision to harness the power of biology for transformative impacts, the company has charted a remarkable journey rooted in innovation and robust research capabilities. Sinobioway primarily delves into the development and commercialization of biological products, focusing on vaccines, antibodies, and other biopharmaceuticals. By emphasizing advanced biotechnologies, the company creates life-enhancing solutions, addressing both common and complex health challenges. Its strategic approach involves a blend of cutting-edge research, partnerships with academic institutions, and collaborations with global pharmaceutical giants, paving the way for market-leading products. Revenue streams for Sinobioway are predominantly driven by its diverse product portfolio that caters to a wide array of medical needs. Through comprehensive R&D, they've effectively commandeered a niche within the preventive medicine sector, particularly with their vaccines, which are in high demand due to increasing health awareness and governmental health initiatives. Additionally, the company fortifies its financial foundation through licensing deals, tapping into global markets and establishing a significant presence internationally. By strategically optimizing production processes and deploying an efficient distribution network, Sinobioway ensures its biomedicine products reach various demographics, thereby anchoring its position in the bioscience industry while continually seeking growth and expansion opportunities beyond local confines.

Intrinsic Value
3.06 CNY
Overvaluation 71%
Intrinsic Value
Price
S

See Also

What is Shandong Sinobioway Biomedicine Co Ltd's Free Cash Flow?
Free Cash Flow
-4.9m CNY

Based on the financial report for Jun 30, 2024, Shandong Sinobioway Biomedicine Co Ltd's Free Cash Flow amounts to -4.9m CNY.

What is Shandong Sinobioway Biomedicine Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
49%

Over the last year, the Free Cash Flow growth was 96%. The average annual Free Cash Flow growth rates for Shandong Sinobioway Biomedicine Co Ltd have been 56% over the past three years , 49% over the past five years .

Back to Top